Introduction {#s1}
============

The ends of eukaryotic chromosomes are capped by telomeres, which are composed of repeated hexanucleotide DNA sequences \[(TTAGGG)*n*\] averaging from 5 to 15 kb in humans ([@DMM025130C96]) and an associated protein complex known as 'shelterin' ([@DMM025130C41]). Telomeres are crucial for genome stability: they prevent chromosome ends from engaging in illegitimate repair and ensure their maintenance by recruiting the enzyme telomerase, a reverse transcriptase that elongates telomeres ([@DMM025130C41]).

In humans, telomerase is found active particularly in germ cells and certain adult stem cells, and can be transiently upregulated by cells of the immune system ([@DMM025130C71]; [@DMM025130C72]; [@DMM025130C79]; [@DMM025130C133]). In contrast, the majority of differentiated somatic cells have no detectable levels of telomerase ([@DMM025130C79]). Consequently, telomeres shorten with each round of cell division and with aging ([@DMM025130C62]). Cell turnover, however, is not sufficient to predict how fast tissues lose telomere sequences ([@DMM025130C39]). Accordingly, alternative mechanisms have been proposed to contribute to telomere shortening, including post-replicative processing by exonucleases (such as Apollo and Exo1) ([@DMM025130C32]; [@DMM025130C136]) and oxidative stress ([@DMM025130C101]; [@DMM025130C103]; [@DMM025130C115]).

Telomeres that have been shortened to critical lengths are recognized as DNA double-strand breaks (DSBs) and trigger mechanisms constituting DNA-damage responses (DDRs) that culminate in a specific type of cell-cycle arrest, designated by Hayflick as 'replicative senescence' ([@DMM025130C38]; [@DMM025130C65]; [@DMM025130C102]; [@DMM025130C123]). Senescence induced by short telomeres can lead to both favourable and deleterious consequences. On the positive side, this phenomenon can avert the indefinite proliferation of malignant tumour cells, and thus prevent the development of cancer ([@DMM025130C79]). On the negative side, it limits the function of stem cells that are necessary for tissue regeneration, potentially contributing to the loss of tissue homeostasis observed in aging ([@DMM025130C14]; [@DMM025130C27]).

A prominent role for telomeres in aging has been supported by studies showing that mutations in genes crucial for telomere maintenance cause degenerative disorders that result in premature-aging symptoms (progeria-type diseases dubbed 'telomeropathies') ([@DMM025130C143]; [@DMM025130C30]). An example of a multisystem disorder caused by defective telomere maintenance is dyskeratosis congenita (DC). Individuals with DC often carry mutations in *TERT* and *TERC*, which encode the catalytic and RNA subunits of telomerase, respectively. Other genes that have been implicated in the disease include *TIN2* (TERF1-interacting nuclear factor 2), which encodes a component of shelterin, and genes involved in the biogenesis and trafficking of telomerase, including *DKC1* (dyskerin; dyskeratosis congenita 1), *NOP10* (nucleolar protein 10) and *TCAB1* (telomerase Cajal body protein 1) ([@DMM025130C8]; [@DMM025130C66]; [@DMM025130C92]; [@DMM025130C122]; [@DMM025130C126]; [@DMM025130C125]; [@DMM025130C129]; [@DMM025130C142]). DC individuals have much shorter telomeres than their unaffected relatives and die prematurely, presenting characteristic dysfunctional phenotypes in their first decade of life, including nail dystrophy, oral leukopathies and hyperpigmentation of the skin ([@DMM025130C82]). Other characteristics reminiscent of aging can develop later on, such as premature greying of the hair, hair loss (alopecia), a condition affecting teeth known as taurodontism, osteoporosis and cancer ([@DMM025130C7]). The majority of affected individuals die from bone-marrow failure due to an impaired renewal capability of hematopoietic stem cells (HSCs) ([@DMM025130C16]; [@DMM025130C76]). Hoyeraal-Hreidersson syndrome (HHS) is a rare and severe variant of DC. In addition to DC symptoms, HHS is clinically characterized by cerebellar hypoplasia and microcephaly ([@DMM025130C1]). Other exceptionally rare variations of DC include Revesz syndrome and Coats plus syndrome ([@DMM025130C107]; [@DMM025130C116]). Interestingly, these disorders exhibit a pattern of genetic anticipation, in which later generations of carriers have shorter telomeres and suffer from an earlier onset of disease with aggravated symptoms ([@DMM025130C73]). *TERT* heterozygote carriers can express some form of DC and even wild-type children inherit shorter telomeres (than average) from their parents ([@DMM025130C34]). The reason why these children would inherit and maintain shorter telomeres in the presence of telomerase remains unclear.

To complement studies of humans with DC, late-generation telomerase-knockout mice (obtained by incrossing telomerase mutants for several generations, typically three or four) have been used. These mice provide a crucial laboratory tool to assess how telomere shortening promotes aging ([@DMM025130C23]; [@DMM025130C109]). However, these mice fail to demonstrate full penetrance of DC symptoms, possibly owing to the fundamental differences in telomere length, cell immortalization and entry into senescence that distinguish mouse cells from human cells ([@DMM025130C135]). This has fuelled the characterization of alternative telomerase-deficient vertebrate animals to more effectively bridge the gap between model organisms and humans in the study of telomere biology and aging. This Review offers a synthesis of the primary discoveries made in zebrafish models that have furthered our understanding of how short telomeres or the absence of telomerase can contribute to aging (from cellular senescence to tissue dysfunction) and disease (DC and cancer). We discuss the similarities between zebrafish telomere biology and mammalian (mouse and human) telomere biology. Finally, we raise awareness of questions that remain unsolved in the telomere-aging-disease triangle, in particular how this interplay is mediated at the molecular level and highlight the advantageous features of zebrafish -- such as rapid development and ease of drug screening -- that could help to address these questions in the near future.

Zebrafish telomeres in aging -- why study them? {#s2}
===============================================

Most short-lived rodent species die before telomeres reach the lengths found in human senescent cells ([@DMM025130C52]; [@DMM025130C56]; [@DMM025130C62]). The common lab mouse, which has been the primary model to date for studying how telomere shortening impacts organismal homeostasis, has telomeres ranging from 20-150 kb in length ([@DMM025130C81]). Telomeres in mice are thus four- to ten-times bigger than telomeres in humans, whose average telomeres generally range from 5-15 kb ([@DMM025130C96]; [@DMM025130C135]). Strikingly, telomerase-deficient lab mice are viable through several generations of incrossing (mating of animals that are homozygous for the *TERT* or *TERC* loci). Previous studies showed that only later generations displayed severe disease phenotypes (e.g. premature death, infertility, intestinal atrophy, bone-marrow failure) ([@DMM025130C23]; [@DMM025130C91]). This contrasts with the immediate (first generation) tissue-dysfunction phenotypes and decreased lifespan of humans carrying mutations in telomerase genes. One single study found, however, that the first generation (G1) of inbred *Terc^−/−^* mice already exhibited reductions in medium and maximum survival ([@DMM025130C53]). It remains unclear whether the discrepancies found between these findings and those reported in earlier studies involving telomerase-knockout mice are related to strain differences.

Thus, there is a high demand for the development of alternative vertebrate models that, like humans, require telomerase for normal lifespan and tissue homeostasis. In this regard, two short-lived fish species with human-like telomeres have emerged as promising complementary vertebrate models: zebrafish (5-15 kb telomeres) and the GRZ killifish strain (6-8 kb telomeres) ([@DMM025130C2]; [@DMM025130C5]; [@DMM025130C18]; [@DMM025130C29]; [@DMM025130C61]; [@DMM025130C68]; [@DMM025130C75]; [@DMM025130C80]).

The GRZ killifish inbred strain offers a great advantage in studies of aging: of all vertebrate models bred in laboratory conditions, it has the shortest natural lifespan, with a maximum of 6 months ([@DMM025130C61]). However, unlike in humans, telomere shortening with age is not observed in the GRZ strain ([@DMM025130C63]). In addition, although telomerase deficiency in killifish causes premature tissue dysfunction, including gut villi atrophy, infertility, loss of blood cellularity and epithelial adenomatous changes, it appears not to influence the lifespan of the organism, nor embryo telomere length, in the first generation ([@DMM025130C61]). Crucially, it remains to be shown whether the tissue degeneration observed in telomerase killifish mutants is a consequence of telomere shortening during adulthood. Future studies should also evaluate the possibility of using other killifish strains, such as the wild-derived strain MZM-0403 (a short-lived strain with human-like telomeres that shorten with age), as alternative models for telomere research ([@DMM025130C63]).

The use of zebrafish, which has a maximum lifespan of 43 months ([@DMM025130C29]), as a model to study the effects of telomerase deficiency and telomere shortening in aging, cancer and regeneration has been growing at a fast pace in the past decade ([@DMM025130C5]; [@DMM025130C18]; [@DMM025130C29]; [@DMM025130C68]; [@DMM025130C75]; [@DMM025130C132]). The functional domains of zebrafish telomerase are highly similar to their human counterparts \[N-terminus, telomerase RNA (TR)-binding site and reverse transcriptase (RT) motifs\] ([@DMM025130C75]; [@DMM025130C90]). As in humans, the zebrafish telomerase promoter is activated by Myc and NF-κB ([@DMM025130C90]). Telomerase expression, although detected in most zebrafish tissues, declines with age ([@DMM025130C4]; [@DMM025130C90]). Consequently, as in humans, telomeres also shorten significantly over time in tissues such as blood and muscle ([@DMM025130C4]; [@DMM025130C29]). Three interesting aspects of telomere shortening in zebrafish further substantiate that this organism is an effective model to study human telomere biology: As reported for humans ([@DMM025130C39]), telomere shortening occurs both in high-turnover (e.g. gut) and low-turnover (e.g. muscle) organs in zebrafish, regardless of differences in proliferation rates ([@DMM025130C29]). What determines shortening in tissues with lower proliferation rates is unknown, but causality between higher reactive oxygen species (ROS) levels and telomere shortening remains to be tested. ROS are known to cause genotoxic damage particularly in G-rich DNA regions, including telomeres ([@DMM025130C67]; [@DMM025130C101]), which could result in their attrition.In zebrafish gut and muscle tissue, pronounced telomere erosion occurs within the first 1.5 years, after which no significant shortening can be detected. In humans, a similar trend of accentuated shortening during puberty followed by stabilization in length at later ages has been described ([@DMM025130C15]; [@DMM025130C111]; [@DMM025130C119]) and could reflect the elimination of cells with extremely short telomeres, possibly via apoptosis.The accumulation of short telomeres and of damage at telomeres over time in zebrafish anticipates the onset of tissue-specific phenotypes of aging, such as intestinal inflammation, and of aging-associated diseases, such as cachexia and, surprisingly, cancer (contrary to several oncogene-driven telomerase-knockout models) ([@DMM025130C29]) ([Fig. 1](#DMM025130F1){ref-type="fig"}). Fig. 1.**Telomeres shorten at different rates, anticipating local and systemic tissue dysfunction in zebrafish aging.** Telomeres shorten naturally over time in specific zebrafish organs, such as the gut and muscle (but not testes), regardless of differences in proliferation rates. This shortening, together with the accumulation of local telomere damage, precludes the onset of tissue-dysfunction events in aging, including intestinal inflammation and sarcopenia. Critically short telomeres in the gut and muscle might prove to be sufficient in disrupting homeostasis in unrelated tissues, where telomeres do not shorten, by generating systemic signals (purple) of dysfunction that create a 'disease-permissive' environment.

Altogether, these studies strongly support the hypothesis that, similarly to in humans but in contrast to in GRZ killifish, telomere shortening acts as a major contributor to the increase in DNA damage, tissue dysfunction and disease observed in zebrafish aging ([Fig. 1](#DMM025130F1){ref-type="fig"}). Accordingly, many larval and adult models have emerged to directly explore how these variables are interconnected. These are reviewed in the next sections and some provocative questions of where telomere research in zebrafish could lead us are raised.

A model of vertebrate accelerated aging: the telomerase mutant zebrafish {#s3}
========================================================================

The crucial need to evaluate how telomere shortening regulates tissue homeostasis in vertebrates with human-like telomeres has led to efforts to characterize the telomerase-deficient zebrafish strain *tert^hu3430^*^/*hu3430*^ ([@DMM025130C5]; [@DMM025130C68]) ([Table 1](#DMM025130TB1){ref-type="table"}). First-generation *tert^hu3430^*^/*hu3430*^ zebrafish, hereafter referred to as *tert^−/−^*, have shorter telomeres than wild-type zebrafish and die prematurely ([@DMM025130C5]; [@DMM025130C68]). *tert^−/−^* zebrafish develop several degenerative phenotypes. Homeostasis is disrupted in *tert^−/−^* highly proliferative tissues (e.g. testis and gut), resulting in infertility, gastrointestinal atrophy and inflammation. Low-proliferation tissues, such as muscle and eye, also display dysfunctional phenotypes, including sarcopenia (muscle) and retinal atrophy (eye) ([@DMM025130C5]; [@DMM025130C68]). Strikingly, the majority of these tissue-dysfunction events tightly phenocopy those that occur during natural zebrafish aging ([@DMM025130C29]). In addition, *tert^−/−^* zebrafish exhibit an accelerated onset of several age-related diseases, such as cachexia, gas-bladder infection and cancer (discussed below). These studies substantiate that the telomerase mutant zebrafish, an organism with artificially shortened telomeres, is an effective model to study the responses elicited by natural telomere erosion in physiological aging. Table 1.**Zebrafish models for telomere and telomerase research**

As in mammals, telomerase dosage seems to be a crucial factor for zebrafish homeostasis. This is underscored by the observation that more than 50% of a *tert^−/−^* incross progeny (second-generation *tert^−/−^* mutants or G2 *tert^−/−^*) die within the first week of life ([@DMM025130C5]), a phenomenon that can be partially rescued by restoring telomerase activity ([@DMM025130C5]). The severity of developmental defects found in G2 *tert^−/−^* zebrafish is proportional to the amount of critically short telomeres, measured as 'telomere free-ends' ([@DMM025130C5]). Thus, telomerase deficiency causes a disease anticipation phenomenon in zebrafish, reproducing what is typically observed in human telomeropathies.

Further supporting a vital role for telomeres in zebrafish homeostasis, mutants for the telomere repeat binding factor 2 (Terf2 in mammals; Terfa in zebrafish), *terfa^hi3678/hi3678^*, are embryonically lethal ([Table 1](#DMM025130TB1){ref-type="table"}). In addition, these embryos demonstrate premature retinal neurodegeneration and senescence in the brain and spinal cord ([@DMM025130C85]). Adult *terfa* heterozygotes, although viable, exhibit signs of premature retinal degeneration and have a shorter lifespan compared with wild type ([@DMM025130C85]) ([Table 1](#DMM025130TB1){ref-type="table"}).

Many exciting questions follow these ground-breaking studies using adult zebrafish models, perhaps the most pressing being whether telomerase-activating therapeutics can delay zebrafish aging. Single telomerase gene therapy treatments using recombinant non-integrative adeno-associated viruses (AAVs) seem to be sufficient to delay the incidence of aging-associated pathologies and extend wild-type mouse lifespan, an animal with comparatively long telomeres ([@DMM025130C20]). Is whole-body telomerase overexpression sufficient to delay aging in zebrafish, an animal with human-like telomeres? If targeted to specific tissues where telomeres shorten over time, is telomerase overexpression sufficient to prevent local and systemic damage in aging? Is there an optimal therapeutic time window before age-associated defects become irreversible? Answers to these questions will provide crucial clues for the development of telomerase-based rejuvenation therapies.

The complex interplay between telomeres, telomerase and cancer {#s4}
==============================================================

Telomere shortening commits cells to growth arrest after a certain number of divisions -- a mechanism that acts as a robust suppressor of tumour growth ([@DMM025130C62]; [@DMM025130C65]). Cells with short telomeres, however, can find ways to bypass replicative senescence, such as acquiring a mutation in the cell-cycle regulator p53 that favours continuing proliferation ([@DMM025130C35]). Resumed proliferation ramps up chromosomal instability ('crisis'), resulting in massive death mediated by mitotic telomere deprotection -- where telomeres can no longer be distinguished from DNA damage -- and chromosome fusions ([@DMM025130C35]; [@DMM025130C64]). Such events favour the selection of mutations that promote activation of telomere maintenance programs that facilitate sustained proliferation -- 90% of human cancers achieve this by reactivating telomerase ([@DMM025130C79]; [@DMM025130C94]; [@DMM025130C117]). Thus, although telomere shortening might have evolved to keep cancer at bay, it also promotes the selection of unstable cells that can effectively bypass tumour-suppressor checkpoints ([@DMM025130C12]).

Surprisingly, telomerase activity is not rate-limiting for zebrafish tumorigenesis: *tert^−/−^* mutants develop spontaneous tumours at a similar frequency as wild-type animals ([@DMM025130C29]). Similar to other aging-related diseases, cancer emerges prematurely in *tert^−/−^* zebrafish (as early as 4 months) bearing the characteristics of normal old age. Similar to wild-type zebrafish, *tert^−/−^* cancer has an 8% incidence, consists mainly of germ cell tumours, hematopoietic neoplasias and intestinal adenocarcinomas, and has a 40% invasion rate ([@DMM025130C29]). It is not obvious how this reconciles with the scenario in mice, in which the effects of telomerase deficiency in tumorigenesis vary according to genetic context and p53 status ([@DMM025130C10]; [@DMM025130C12]; [@DMM025130C11]). Indeed, late-generation telomerase-knockout mice have either higher cancer rates ([@DMM025130C12]; [@DMM025130C21]; [@DMM025130C109]), lower cancer rates (sometimes with more initiation events) ([@DMM025130C48]; [@DMM025130C57]; [@DMM025130C59]; [@DMM025130C74]; [@DMM025130C110]) or unaltered cancer rates ([@DMM025130C6]). These studies in mice indicate the need for a deepened understanding of how telomerase knockout affects cancer incidence, and the study of different oncogene-expressing zebrafish transgenic lines could meet this need.

Even if tumours arise in short-telomere *tert^−/−^* zebrafish cells, their growth and progression will expectedly require the activation of a telomere-maintenance mechanism. The (yet undemonstrated) explanation is that *tert^−/−^* zebrafish tumours are efficient in engaging mechanisms of alternative lengthening of telomeres (ALT) ([@DMM025130C26]). Several studies support that ALT is achieved by homologous recombination (HR) mechanisms at telomeres. Consistently, DNA tags inserted into telomeres are copied between chromosome ends in ALT cell lines, which are telomerase-negative, but not in telomerase-positive cells ([@DMM025130C45]). ALT is thought to occur in approximately 10% of human cancers ([@DMM025130C117]) and is more prevalent in tumours of mesenchymal origin ([@DMM025130C89]). Because zebrafish cancer rates are not affected by the absence of telomerase, it is tempting to speculate that ALT could constitute a central pathway in telomere maintenance in tumorigenesis. In the context of *tert*+ tumors, telomerase might simply provide a more stable (rather than a more common) solution to promote genome stability and outcompete ALT-based mechanisms. Consistent with this idea, recent studies show that ALT telomeres promote genome instability by recombining chromosome ends with interstitial regions ([@DMM025130C93]).

Characterizing ALT is therefore of crucial importance for the study of telomere dynamics in zebrafish cancer. Because the zebrafish genome lacks a clear promyelocytic leukemia (*PML*) gene ([@DMM025130C124]), it is impossible to assess the presence of ALT by probing for characteristic complexes of promyelocytic leukemia nuclear bodies associated with telomeres, known as APBs (ALT-associated PML bodies). ALT tumours are nevertheless characterized by other features, including heterogeneous telomere length (with very short and very long sequences) ([@DMM025130C26]), and the presence of extrachromosomal telomeric DNA that forms double-stranded (t-circles) ([@DMM025130C130]) and single-stranded (C- or G-circles) ([@DMM025130C69]) circles. In addition, several recombination proteins are necessary for telomere maintenance in ALT cells, including the MRN complex (MRE11, RAD50 and NBS1) ([@DMM025130C77]; [@DMM025130C141]), subunits of the SMC5/6 (structural maintenance of chromosomes 5/6) complex ([@DMM025130C105]), FEN1 (flap structure-specific endonuclease 1) ([@DMM025130C113]), MUS81 (structure-specific endonuclease subunit) ([@DMM025130C138]) and FANCD2 (Fanconi anemia group D2) ([@DMM025130C47]). Looking at a combination of these features will help determine whether ALT is a prevalent mechanism in zebrafish tumorigenesis. This could be of consequence if we are to consider the potential use of zebrafish for performing chemical screens for anti-ALT therapies with possible relevance to certain human cancers.

Zebrafish models for dyskeratosis congenita {#s5}
===========================================

As detailed earlier, DC is a bone-marrow-failure disorder characterized by shortened telomeres, defective stem cell maintenance and highly heterogeneous phenotypes affecting predominantly tissues that require high rates of turnover, such as skin and lung epithelium and bone marrow ([@DMM025130C82]). Although the majority of individuals with DC die from bone-marrow failure, the associated increased risk of cancer also contributes to DC mortality ([@DMM025130C3]).

All mutations identified to date in DC individuals are found in components of telomerase and in genes that are required for its biogenesis, or in telomere-stabilizing elements ([@DMM025130C125]). All of these mutations lead to defects in telomere biology and affect the renewal capabilities of HSCs ([@DMM025130C25]; [@DMM025130C44]). Mutations in telomerase genes (*TERC* and *TERT*) are autosomal dominant owing to telomerase haploinsufficiency and show disease anticipation associated with progressive telomere shortening ([@DMM025130C125]). G1 *tert^−/−^* zebrafish have premature aging symptoms, with the most apparent phenotype being the sharp decline in the mean life expectancy ([@DMM025130C5]; [@DMM025130C68]). Interestingly, *tert*^+/−^ zebrafish also have reduced longevity compared with wild type, while G2 *tert*^−/−^ fish die before the second week of life, suggesting that telomere length is essential for zebrafish lifespan ([@DMM025130C5]) ([Table 1](#DMM025130TB1){ref-type="table"}). Thus, as in humans, telomerase haploinsufficiency in zebrafish leads to telomere shortening and reduced longevity, despite the presence of telomerase. Moreover, the decrease in lifespan in zebrafish is proportional to the degree of telomere shortening ([@DMM025130C5]).

Surprisingly, mutations affecting *TERC* (such as G58A) are not associated with impaired telomerase activity *in vitro* ([@DMM025130C33]), despite leading to particularly severe disease in humans ([@DMM025130C125]; [@DMM025130C33]). Various lines of evidence have shown that the cancer-promoting activity of TERC seems to be independent of *in vitro* telomerase activity, consistent with the hypothesis that TERC might play a non-canonical role in DC pathogenesis. For example, telomerase can promote tumorigenesis in mice independently of net telomere elongation ([@DMM025130C22]). Moreover, several groups have shown that mice with transgenic expression of *TERT* have a higher susceptibility to develop tumours in the absence of telomere length differences ([@DMM025130C13]; [@DMM025130C28]; [@DMM025130C58]) and that this effect is dependent on the presence of TERC ([@DMM025130C31]). These observations, together with the ability of TERC to specifically bind to 2198 sites in the human genome ([@DMM025130C37]), have led to the hypothesis that TERC has non-canonical cellular functions, potentially involving the regulation of gene expression.

Non-canonical roles for telomerase have also been described in zebrafish. Genetic depletion of *terc* in zebrafish embryos \[using antisense morpholino (MO)-mediated knockdown technology\] resulted in dramatic loss of neutrophils and monocytes independent of telomerase activity or telomere shortening ([@DMM025130C2]) ([Table 1](#DMM025130TB1){ref-type="table"}). Similarly, a study identified a role for *tert* in promoting the development of hematopoietic cells in zebrafish, through a mechanism that is independent of its telomerase activity and function in telomere lengthening ([@DMM025130C75]). The authors showed that *tert* morphant zebrafish embryos exhibit abnormal differentiation and apoptosis of hematopoietic stem and/or progenitor cells, subsequently leading to the circulation of immature blood cells and anaemia without any obvious telomere shortening ([@DMM025130C75]) ([Table 1](#DMM025130TB1){ref-type="table"}). This mirrors the low number of circulating blood cells -- including red blood cells, white blood cells and platelets -- observed in human DC ([@DMM025130C82]).

DC also encompasses genes involved in telomerase biogenesis. Dyskerin (DKC1), a member of the H/ACA ribonucleoprotein (RNP) complex, was the first gene discovered to be responsible for the X-linked severe form of DC. DKC1 is involved in telomerase function through its RNA subunit, which contains an H/ACA RNA motif, and integrity of this motif is essential for assembly and stability of the human telomerase RNP ([@DMM025130C127]). Knockdown of *dkc1* revealed a role in zebrafish hematopoiesis ([@DMM025130C140]). Downregulation of *dkc1* results in HSC failure, increased p53 expression and defective ribosomal biogenesis, all without detectable changes in telomerase activity ([@DMM025130C140]) ([Table 1](#DMM025130TB1){ref-type="table"}). Mutations in two other H/ACA RNP complex genes, *NHP2* ([@DMM025130C128]) and *NOP10* ([@DMM025130C129]), have also been reported in DC. In line with the previously discussed zebrafish DC models, *nop10* mutant embryos also fail to form HSCs and, again, these mutants display no telomere shortening ([@DMM025130C104]) ([Table 1](#DMM025130TB1){ref-type="table"}).

In all four of these zebrafish models, telomere lengths are not significantly altered, supporting a model for DC pathogenesis where mutations in *TERC*, *TERT*, *DKC1* and *NOP10* contribute to bone-marrow failure through a telomere-lengthening- independent mechanism. In line with these observations, some of the previously reported disease-associated human TERT alleles give rise to a near-normal telomerase enzyme activity, suggesting that these mutations cause the disease by affecting telomerase functions that are not related to its enzymatic activity ([@DMM025130C137]). These findings are in apparent contradiction with those obtained in telomerase*-*deficient mice, which exhibit defects in the haematopoietic system only when telomeres are critically short ([@DMM025130C91]). The most obvious explanation is that there might be developmental and/or physiological compensations in mice that probably do not exist in humans or fish.

Despite the concordance between findings in zebrafish and studies of human clinical samples, it is important to highlight that the zebrafish studies use MOs to downregulate the expression of *tert*, *terc* and *dkc1*. Recently, the use of this technology has been questioned throughout the zebrafish community. Unfortunately, some morphant phenotypes have been proven to be due to off-target effects, suggesting that it is always preferable to target exons encoding domains that are necessary for protein function or generating segmental deletions, rather than to use MOs ([@DMM025130C87]). Given the ease of use of current site-specific nuclease technologies, most notably the CRISPR systems, it will be crucial to generate new zebrafish lines, ideally carrying mutations similar to those found in humans with DC, in order to confirm the importance of the non-canonical functions of telomerase.

How do short telomeres drive aging? {#s6}
===================================

As mentioned earlier, induced telomere shortening (in telomerase mutants) is sufficient to cause a cascade of tissue dysfunctional events in both high- and low-proliferation tissues. However, the mechanistic basis underlying loss of homeostasis in the majority of these tissues is still not understood. Deciphering whether these mechanisms are also relevant in contexts of natural aging is crucial to understand the impact of short telomeres in age-associated diseases.

Telomeres shortened to critical lengths become indistinguishable from DNA double-strand breaks triggering DDRs ([@DMM025130C41]), which results in the activation of p53 ([@DMM025130C38]; [@DMM025130C55]; [@DMM025130C60]). Accordingly, p53 acts as a major executioner of short-telomere-induced defects in highly proliferative tissues of both mice ([@DMM025130C35]) and zebrafish ([@DMM025130C5]; [@DMM025130C68]). Deletion of *p53* is sufficient to prevent germ-cell apoptosis and infertility in late-generation *Terc^−/−^* mice ([@DMM025130C35]). However, this comes at the high cost of increased genome instability and cancer ([@DMM025130C12]; [@DMM025130C35]; [@DMM025130C99]). Although p53 deficiency rescues premature death, cell-proliferation defects and reduced gut-villi length of *tert^−/−^* zebrafish ([@DMM025130C5]; [@DMM025130C68]) ([Table 1](#DMM025130TB1){ref-type="table"}), its effect on tumour incidence has not been described. Most likely, *tert^−/−^ tp53^−/−^* zebrafish will display an abnormally high incidence of cancer and early onset of tumors, given that these features characterize the single *tp53^−/−^* mutants \[28% of fish develop malignant peripheral-nerve-sheath tumors by 8 months (Berghmans et al., 2005)\] and the single *tert^−/−^* mutants (where cancer appears as early as 4 months) ([@DMM025130C29]). Alternatively, given that most *tert^−/−^* phenotypes related to aging are suppressed in the absence of p53, it is also conceivable that the onset of spontaneous tumours could be delayed in *tert^−/−^ tp53^−/−^* zebrafish.

Which molecular players act downstream of p53 to disrupt tissue homeostasis in *tert^−/−^* zebrafish? A starting point to address this question would be to investigate the molecular mechanisms already described to mediate tissue dysfunction in late-generation telomerase-knockout mice ([Fig. 2](#DMM025130F2){ref-type="fig"}), namely:

1.  Type I: activation of the cell-cycle inhibitor p21 together with p53-dependent modulator of apoptosis (PUMA). These molecules are known to limit stem cell proliferation and the regeneration capacities of high-turnover organs (e.g. intestine, hematopoietic tissue) in G3/G4 *Terc^−/−^* mice ([@DMM025130C36]; [@DMM025130C120]).

2.  Type II: repression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha/beta (PGC1α/β), master regulators of mitochondrial biogenesis \[possibly mediated by inhibition of insulin-like growth factor 1 (IGF-1) and mammalian target of rapamycin (mTOR) signalling\]. Reduction of PGC1α/β lowers oxidative defence mechanisms and gluconeogenesis, resulting in an accumulation of ROS ([Fig. 2](#DMM025130F2){ref-type="fig"}). Altogether, these events have been proposed to underlie dysfunction of more quiescent organs (e.g. heart) in G3/G4 *Terc^−/−^/Tert^−/−^* mice ([@DMM025130C95]; [@DMM025130C114]). Fig. 2.**Pathways modulated by the short-telomere--p53 axis.** Telomere dysfunction, as well as exogenous genotoxic agents and deficiencies in DNA repair, activates p53 ([@DMM025130C35]), causing PUMA-mediated apoptosis ([@DMM025130C120]) and p21 cell-cycle arrest, and, consequently, cell senescence ([@DMM025130C36]). p53 upregulation also leads to impairments in energy homeostasis and potential suppression of IGF-1 signalling, which result in repression of master regulators (such as PGC1α/β) of mitochondrial biogenesis. This leads to mitochondrial dysfunction and, consequently, increased ROS levels, which promote further damage at telomeres. ROS, reactive oxygen species. For further information and references, see the main text.

Importantly, activation of type I or II mechanisms might not be mutually exclusive; instead, these processes could occur simultaneously within an individual tissue undergoing telomere attrition. Because organs are composed of multiple cell types with a wide spectrum of proliferative profiles, this raises the intriguing question: which cells within a tissue undergoing telomere attrition invoke which mechanism? What determines the choice?

There is already compelling evidence showing that stem cells with short telomeres typically activate type I mechanisms, undergoing growth arrest and apoptosis in the intestinal, skin, brain and hematopoietic tissues ([@DMM025130C36]; [@DMM025130C49]; [@DMM025130C51]; [@DMM025130C106]; [@DMM025130C120]; [@DMM025130C134]). A recent study by Rudolph and colleagues further demonstrated that this occurs only in stem cells that are actively cycling (and not in those lying in a quiescent state), presumably to prevent transmission of aberrant genotoxic damage to progenitor cells ([@DMM025130C132]). We still do not know how cells other than adult tissue stem cells deal with telomere-induced DDRs. Testing *in vivo* how the expression of a given gene or pathway is affected in specific telomere dysfunctional cells is a complex task. Zebrafish is an ideal model for addressing these questions, given the possibility for live visualization of the expression of different fluorescent reporters using transparent telomere dysfunctional strains (specifically, albino strains). Nevertheless, there are intrinsic limitations to the use of zebrafish -- an emerging model -- in this area of research: it is a non-mammalian system that either lacks specific cell markers or the reagents to detect them. Furthermore, it remains to be shown whether key metabolic processes in this cold-blooded animal are truly indistinguishable to parallel processes in humans.

Telomerase, telomeres, senescence and tissue repair {#s7}
===================================================

Telomeres function as molecular clocks that keep a record of the replicative history of primary cells ([@DMM025130C62]). Telomere erosion through consecutive cell divisions results in critically short telomeres and elicits replicative senescence ([@DMM025130C65]; [@DMM025130C132]; [@DMM025130C24]). Importantly, short telomeres and senescent cells accumulate in some, but not in all, tissues in aged humans ([@DMM025130C43]), monkeys ([@DMM025130C70]) and mice ([@DMM025130C131]). Since its initial description, our understanding of cellular senescence has evolved dramatically and, today, the concept of senescence has been redefined. In this section, we discuss the importance of senescent cells in an organism, their potential role in tissue regeneration and how this beneficial process can be degraded, particularly in aged tissues.

In zebrafish, telomeres shorten during aging ([@DMM025130C29]; [@DMM025130C4]) and upon loss of telomerase (*tert^−/−^*) ([@DMM025130C5]; [@DMM025130C68]). In both cases, the rate of telomere decline varies between tissues ([@DMM025130C29]). As telomeres shorten, the number of senescent cells increases in the skin ([@DMM025130C83]; [@DMM025130C84]), gut, testes and kidney marrow (head kidney serves as the hematopoietic tissue in zebrafish) ([@DMM025130C29]). *terf2* mutant embryos, which have dysfunctional telomeres, also exhibit high levels of senescence-associated β-galactosidase (SA-β-gal) activity, a widely used *in vitro* marker for cellular senescence as well as of organismal aging in vertebrates ([@DMM025130C85]). Moreover, the brains of old zebrafish express high levels of *smurf2*, a gene implicated in the induction of replicative senescence ([@DMM025130C139]), highlighting short telomeres as important triggers for cell senescence in this teleost ([@DMM025130C9]).

As telomeres get critically short, cellular senescence is activated, and this leads to engagement of various signalling cascades that ultimately activate p53, p16^INK4a^ or both. In mammals, activated p53 induces p21, causing a temporal cell-cycle arrest through the inhibition of cyclin-E--Cdk2 ([@DMM025130C17]). p16^INK4a^ also inhibits cell-cycle progression but does so by targeting cyclin-D--Cdk4 and cyclin-D--Cdk6 complexes ([@DMM025130C118]). Both p21 and p16^INK4a^ act by preventing CDK inactivation of Rb (retinoblastoma protein), resulting in continued repression of *E2F* target genes required for S-phase onset. The relative contribution of p53, p21 or p16^INK4a^ to the initial growth arrest can vary depending on the type of stress. Their function, either alone or in combination, could ultimately result in sustained senescence.

In zebrafish, the p53-p21 pathway is known to exist with relevant functional conservation ([@DMM025130C19]). As for the second effector pathway, the human genetic locus that encodes for p16^INK4a^ also encodes for p15^INK4b^ and a p53 stabilizer, known as p14^ARF^ (p19^ARF^ in zebrafish). Despite the crucial role of the mammalian *INK4b-ARF-INK4a* locus in tumour suppression, its counterpart in zebrafish has not yet been fully characterized. Recently, Sabaawy and colleagues identified one locus homologous to human INK4 in zebrafish, which, surprisingly, was devoid of ARF sequences ([@DMM025130C112]). This locus encodes a single zebrafish *ink4ab* gene, which functions to activate senescence in response to oxidative stress. Thus, zebrafish INK4ab seems to function as a tumour suppressor similar to human p15^INK4B^ and p16^INK4A^ ([@DMM025130C40]; [@DMM025130C50]).

Although established senescence markers are lacking, most senescent cells express the tumour suppressor p16^INK4a^ ([@DMM025130C100]), the levels of which increase with age ([@DMM025130C88]; [@DMM025130C108]). This rise of p16^INK4a^ often coincides with SA-β-gal activity ([@DMM025130C43]). Kishi and colleagues reported SA-β-gal induction during aging in zebrafish ([@DMM025130C83]; [@DMM025130C84]). His group has also been successful in exploiting SA-β-gal staining as a marker for organismal senescence in zebrafish larval models of premature aging ([@DMM025130C85]).

Curiously, senescent cells are still metabolically active and release a complex mixture of extracellular matrix proteases, growth factors, chemokines and cytokines \[collectively known as senescence-associated secretory phenotype (SASP)\] that has significant effects on the surrounding tissue microenvironment. SASP has not yet been described in zebrafish; however, in mammals, it seems to have an important role in recruiting immune and phagocytic cells, such as macrophages, and also activates the motility and proliferation of surrounding cells ([@DMM025130C97]).

Nowadays, senescence has been proposed as an alternative way of cell death. While apoptosis is a rather individual and silent process of cellular suicide, the senescent program requires the involvement of different and complex players to bring about the same result: the clearance of damaged cells (Muñoz-Espín and Serrano, 2014). Still, the ultimate goal of senescence remains unclear. If in the end, senescence is just another way to eliminate damaged cells then why not choose a more direct and faster route of apoptosis?\' It has been proposed that the central role of senescent cells is to initiate a tissue-remodelling process that includes their own elimination. A particularly striking example of the role of senescence in tissue remodelling has been the recent demonstration that senescence participates in developmental processes in vertebrates ([@DMM025130C98]; [@DMM025130C121]), promotes wound healing in mice ([@DMM025130C42]) and contributes to heart regeneration in zebrafish ([@DMM025130C18]).

Zebrafish has become a powerful model for investigating tissue remodelling owing to its capacity to completely regenerate several organ injuries, including brain, spinal cord, retina, heart and fins, even at mature adult stages ([@DMM025130C54]). This ability to regenerate declines with age ([@DMM025130C86]) and, in some organs, is heavily dependent on telomerase activity ([@DMM025130C18]; [@DMM025130C46]) ([Fig. 3](#DMM025130F3){ref-type="fig"}). Bednarek and colleagues have recently shown that ventricular cryoinjury, a process that induces massive cell death similar to that observed in a leading cause of mortality and morbidity in humans -- myocardial infarction -- leads to telomerase hyperactivation in cardiomyocytes, accompanied by a sharp peak of proliferation and a transient elongation of telomeres ([Fig. 3](#DMM025130F3){ref-type="fig"}A). Strikingly, SA-β-gal signalling was induced upon cryoinjury, denoting an initial and transient accumulation of senescent cells ([@DMM025130C18]) ([Fig. 3](#DMM025130F3){ref-type="fig"}A). However, senescence was limited to the injured region and easily cleared upon wound closure. These observations are in line with studies in mice ([@DMM025130C42]), supporting the hypothesis that, in an *in vivo* context, cellular senescence might contribute to tissue remodelling. Fig. 3.**The role of telomerase, telomeres and senescent cells in zebrafish heart regeneration.** Cryoinjury in zebrafish mimics aspects of human myocardial infarction. (A) In wild-type fish, cardiomyocyte proliferation is sharply increased in response to tissue damage, accompanied by an increase in *tert* gene expression, hyperactivation of telomerase and a transient elongation of telomeres (3 dpi). Additionally, there is an accumulation of senescence cells, limited to the injured region (3 dpi) that is cleared upon wound closure (60 dpi) ([@DMM025130C18]). Senescent cells release growth factors and cytokines, which might activate the motility and proliferation of surrounding cells, potentiating tissue remodelling. (B) Aged cardiac tissues, modelled by the absence of telomerase (*tert^−/−^*), are not amenable to tissue remodelling, reflecting a combination of factors, such as proliferative defects, accumulation of DNA-damaged cells and increased senescence (3 dpi and 60 dpi). The difficulty in handling and clearing damaged and senescent cells might overload the tissue with the senescence-associated secretory phenotype (SASP), which potentially contributes to a persistent chronic inflammatory microenvironment that further aggravates tissue dysfunction and impairs proper wound closure ([@DMM025130C18]).

The full benefits of senescence are achieved when the process includes the clearance of the senescent cells, thereby restoring the pre-damage status of the tissue. However, in chronic pathological situations such as aging (as modelled by *tert*^−/−^ fish), cardiac regeneration is impaired and a fibrotic scar remains. This inability to regenerate is primarily due to a strong inhibition of the proliferative response and an accumulation of senescent cells that becomes persistent, and these cells even extend beyond the injured area, further aggravating tissue dysfunction ([@DMM025130C18]) ([Fig. 3](#DMM025130F3){ref-type="fig"}B). The difficulty in handling and clearing damaged and senescent cells could overload the tissue with SASP. This effect results in a persistent chronic inflammatory microenvironment that further aggravates tissue dysfunction and impairs proper regeneration. This process might not be applicable to other types of aged tissues, but constitutes a clear example of how short telomeres and cellular senescence can contribute to age-related defects in tissue regeneration.

Senescence is a double-edged sword, beneficial when it is transient and easily handled but pathological when chronic and unresolved. So, what makes an aged tissue more prone to the accumulation of senescent cells? On the one hand, clearance of senescent cells by the immune system might become impaired with aging, leading to a net accumulation of senescent cells that further aggravate tissue dysfunction via the SASP. On the other hand, senescence might not only affect differentiated cells but also stem and progenitor cells, thus limiting the regenerative capacity of tissues.

Modern society is extremely interested in finding ways to extend human healthy lifespan. There are ongoing pharmacological tests and biological therapies to prevent telomere shortening and accumulation of senescent cells during aging. The impact this will have on human health and disease is currently unknown, although it will likely reveal new biological phenomena. If shortening of telomeres can be prevented and/or senescent cells can be eliminated in human tissues, will this simply delay the very familiar aging phenomenon, or will new types of pathology emerge? These nuances and complexities demand further investigation in order to guide potential new therapeutic options.

Concluding remarks {#s8}
==================

Although telomere shortening is considered a primary culprit of human aging, many questions remain unresolved. How do short telomeres disrupt homeostasis in particular tissues over time? Which precise molecular mechanisms mediate such tissue dysfunction events in aging and premature-aging syndromes such as DC? Addressing these issues has long been hampered by the lack of a vertebrate laboratory model that recaps crucial human features, including a 5-15 kb telomere length range and the immediate onset of degenerative phenotypes upon removal of telomerase.

Ground-breaking discoveries establishing zebrafish as a powerful model for the study of vertebrate telomeres have now filled this need. Because zebrafish has human-like telomeres, deletion of telomerase causes an acceleration of aging-associated diseases and tissue dysfunction events that are observed in the first mutant generation ([@DMM025130C5]; [@DMM025130C29]; [@DMM025130C68]). These not only phenocopy what is observed in human aging, but also reproduce the typical 'anticipation phenomenon' reported in humans with DC (younger generations have an earlier disease onset) ([@DMM025130C5]; [@DMM025130C68]). Thus, phenotypes and molecular mechanisms are both highly conserved from mammalian to zebrafish in the context of telomere dysfunction, rendering this teleost a promising model for telomere research in aging.

From testing the impact of telomerase therapeutics targeted to specific tissues to identifying the molecular mechanisms that mediate short-telomere-induced dysfunction in aging, several challenges lie ahead in the field of telomere research using zebrafish. The unique characteristics of this organism have already proven useful for the identification of important new links between tissue repair, telomerase activation and cellular senescence. Defining how telomere dysfunction is interconnected to other hallmarks of aging is bound to revolutionize the future of aging therapeutics.
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